GLOBAL DRUG DISCOVERY MARKET FORECAST 2017-2024
KEY FINDINGS
The global drug discovery market is projected to grow from $33997million in 2016 to $68683 million by 2024 growing at a CAGR of 9.19% during the forecast period. Major health disorders such as genetic disorders, mental health disorders, diabetes, cardiovascular and other diseases and their prevalence rates among the population drives the market.
MARKET INSIGHTS
The drug discovery market is segmented on the basis of technology and geography. The drug discovery market on the basis of technology is segmented into QPCR, DNA microarrays, protein microarrays, high-throughput screening, mass spectrometry, gel electrophoresis, chromatography, protein and nucleic acid isolation and other technologies. The drug discovery market by geography is segmented into North America, Europe, Asia-Pacific and Rest of the world.
The major market drivers for the growth of drug discovery market are aging population, increased expenditure on healthcare, and rise in lifestyle oriented diseases and fatalities. Contrarily, the delayed processing of government regulations, poor access to the healthcare services and the shift from branded drugs to generic drugs are factors that restraints the market growth.
REGIONAL INSIGHTS
North America holds a colossal market share in the global drug discovery market. NA also accounts for highest consumer of branded drugs. Europe accounts for the second largest market in the global drug discovery market. Asia-Pacific market is projected to grow during the forecast period due to increase in the number of contract research organizations in the region.
COMPETITIVE INSIGHTS
The leading players in the drug discovery market are Johnson And Johnson, Bayer AG Sanofi, AstraZeneca PLC, Pfizer, Merck & Co. INC., Boehringer Ingelheim, INC., Glaxosmithkline LLC, Eli Lily, Roche Holding AG. Sanofi, formerly Sanofi-Aventis.
The global drug discovery market is projected to grow from $33997million in 2016 to $68683 million by 2024 growing at a CAGR of 9.19% during the forecast period. Major health disorders such as genetic disorders, mental health disorders, diabetes, cardiovascular and other diseases and their prevalence rates among the population drives the market.
MARKET INSIGHTS
The drug discovery market is segmented on the basis of technology and geography. The drug discovery market on the basis of technology is segmented into QPCR, DNA microarrays, protein microarrays, high-throughput screening, mass spectrometry, gel electrophoresis, chromatography, protein and nucleic acid isolation and other technologies. The drug discovery market by geography is segmented into North America, Europe, Asia-Pacific and Rest of the world.
The major market drivers for the growth of drug discovery market are aging population, increased expenditure on healthcare, and rise in lifestyle oriented diseases and fatalities. Contrarily, the delayed processing of government regulations, poor access to the healthcare services and the shift from branded drugs to generic drugs are factors that restraints the market growth.
REGIONAL INSIGHTS
North America holds a colossal market share in the global drug discovery market. NA also accounts for highest consumer of branded drugs. Europe accounts for the second largest market in the global drug discovery market. Asia-Pacific market is projected to grow during the forecast period due to increase in the number of contract research organizations in the region.
COMPETITIVE INSIGHTS
The leading players in the drug discovery market are Johnson And Johnson, Bayer AG Sanofi, AstraZeneca PLC, Pfizer, Merck & Co. INC., Boehringer Ingelheim, INC., Glaxosmithkline LLC, Eli Lily, Roche Holding AG. Sanofi, formerly Sanofi-Aventis.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DRIVERS
4.1.1. AGING POPULATION
4.1.2. SPENDING ON HEALTHCARE HAS BEEN INCREASED
4.1.3. INCREASE IN LIFESTYLE ORIENTED DISEASES & FATALITIES
4.2. MARKET RESTRAINTS
4.2.1. GOVERNMENT REGULATIONS DELAYING THE PROCESSES
4.2.2. POOR ACCESS TO THE HEALTHCARE SERVICES IN DEVELOPING MARKETS
4.2.3. MARKET IS SHIFTING FROM BRANDED TO GENERIC DRUGS
4.3. MARKET CHALLENGES
4.3.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
4.4. MARKET OPPORTUNITIES
4.4.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
5. BY TECHNOLOGY
5.1. QPCR
5.2. DNA MICROARRAYS
5.3. PROTEIN MICROARRAYS
5.4. HIGH-THROUGHPUT SCREENING
5.5. MASS SPECTROMETRY
5.6. GEL ELECTROPHORESIS
5.7. CHROMATOGRAPHY
5.8. PROTEIN AND NUCLEIC ACID ISOLATION
5.9. OTHER TECHNOLOGIES
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. COMPETITIVE RIVALRY
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF SUBSTITUTE PRODUCTS
6.2. VALUE CHAIN ANALYSIS
6.3. KEY EXCERPTS OF THE STUDY
6.3.1. RELAXATION IN THE REGULATIONS BY THE GOVERNMENT WHICH STOPS RESEARCHERS FROM DOING RESEARCH.
6.3.2. MARKET LEADERS SHOULD OPEN UP THEIR BRANCHES AND RESEARCH LABS IN EMERGING MARKETS.
6.4. PESTLE ANALYSIS
6.5. OPPORTUNITY MATRIX
6.6. VENDOR LANDSCAPE
7. BY REGION
7.1. NORTH AMERICA
7.1.1. UNITED STATES (U.S.)
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM (UK)
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE (ROE)
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. KOREA
7.3.5. AUSTRALIA
7.3.6. REST OF ASIA-PACIFIC (ROAPAC)
7.4. REST OF THE WORLD (ROW)
7.4.1. MIDDLE EAST AND NORTH AMERICA
7.4.2. AFRICA
8. COMPANY PROFILES
8.1. SANOFI
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SWOT ANALYSIS
8.1.4. STRATEGIC ANALYSIS
8.2. JOHNSON AND JOHNSON
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC ANALYSIS
8.3. ASTRAZENECA PLC
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC ANALYSIS
8.4. BAYER AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC ANALYSIS
8.5. BOEHRINGER INGELHEIM
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SWOT ANALYSIS
8.5.4. STRUCTURAL ANALYSIS
8.6. PFIZER, INC.
8.6.1. COMPANY OVERVIEW
8.6.2. SWOT ANALYSIS
8.6.3. STRATEGIC ANALYSIS
8.7. GLAXOSMITHKLINE LLC
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SWOT ANALYSIS
8.7.4. STRATEGIC ANALYSIS
8.8. ELI LILY
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SWOT ANALYSIS
8.8.4. STRATEGIC ANALYSIS
8.9. MERCK & CO. INC.
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SWOT ANALYSIS
8.9.4. STRATEGIC ANALYSIS
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SWOT ANALYSIS
8.10.4. STRATEGIC ANALYSIS
TABLE LIST
TABLE 1 FACT SHEET OF GLOBAL FATALITIES
TABLE 2 GLOBAL QPCR MARKET, BY REGION, 2016-2024, (IN $MILLION)
TABLE 3 GLOBAL DNA MICROARRAYS, BY REGION, 2016-2024, (IN $MILLION)
TABLE 4 GLOBAL PROTEIN MICROARRAYS, BY REGION, 2016-2024(IN $MILLION)
TABLE 5 GLOBAL HIGH THROUGHPUT SCREENING, BY REGION, 2016-2024(IN $MILLION)
TABLE 6 GLOBAL MASS SPECTROMETRY, BY REGION, 2016-2024(IN $MILLION)
TABLE 7 GLOBAL GEL ELECTROPHORESIS MARKET, BY REGION, 2016-2024, (IN $MILLION)
TABLE 8 GLOBAL CHROMATOGRAPHY MARKET, BY REGION, 2016-2024 (IN $MILLION)
TABLE 9 GLOBAL PROTEIN AND NUCLEIC ACID ISOLATION MARKET, BY REGION, 2016-2024 (IN $MILLION)
TABLE 10 GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, 2016-2024 (IN $MILLION)
TABLE 11 GLOBAL DRUG DISCOVERY MARKET, BY REGION, 2016-2024, (IN $MILLION)
TABLE 12 FATALITY IN EUROPE IN 2012
FIGURES LIST
FIGURE 1 GLOBAL DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 2 GLOBAL DRUG DISCOVERY MARKET SHARE, BY TECHNOLOGY, 2016 & 2024
FIGURE 3 GLOBAL QPCR MARKET, 2016-2024 (IN $MILLION)
FIGURE 4 GLOBAL DNA MICROARRAYS MARKET, 2016-2024 (IN $MILLION)
FIGURE 5 GLOBAL PROTEIN MICROARRAYS MARKET, 2016-2024 (IN $MILLION)
FIGURE 6 GLOBAL HIGH THROUGHPUT SCREENING MARKET, 2016-2024 (IN $MILLION)
FIGURE 7 GLOBAL MASS SPECTROMETRY MARKET, 2016-2024 (IN $MILLION)
FIGURE 8 GLOBAL GEL ELECTROPHORESIS MARKET, 2016-2024 (IN $MILLION)
FIGURE 9 GLOBAL CHROMATOGRAPHY MARKET, 2016-2024 (IN $MILLION)
FIGURE 10 GLOBAL PROTEIN AND NUCLEIC ACID ISOLATION MARKET, 2016-2024 (IN $MILLION)
FIGURE 11 GLOBAL OTHER TECHNOLOGIES MARKET, 2016-2024 (IN $MILLION)
FIGURE 12 NORTH AMERICA DRUG DISCOVERY MARKET, 2016-2024, (IN $ MILLION)
FIGURE 13 COUNTRY-WISE MARKET SHARE, 2016
FIGURE 14 UNITED STATES DRUG DISCOVERY MARKET, 2016-2024, (IN $ MILLION)
FIGURE 15 CANADA DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 16 EUROPE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 17 COUNTRY-WISE MARKET SHARE, 2016
FIGURE 18 UNITED KINGDOM DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 19 FRANCE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 20 GERMAN DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 21 SPAIN DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 22 ITALY DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 23 REST OF EUROPE (ROE) DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 24 ASIA-PACIFIC DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 25 COUNTRY-WISE MARKET SHARE, 2016
FIGURE 26 INDIA DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 27 CHINA DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 28 JAPAN DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 29 KOREA DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 30 AUSTRALIA DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 31 REST OF ASIA-PACIFIC (ROAPAC) DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 32 REST OF THE WORLD (ROW) DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
4.1. MARKET DRIVERS
4.1.1. AGING POPULATION
4.1.2. SPENDING ON HEALTHCARE HAS BEEN INCREASED
4.1.3. INCREASE IN LIFESTYLE ORIENTED DISEASES & FATALITIES
4.2. MARKET RESTRAINTS
4.2.1. GOVERNMENT REGULATIONS DELAYING THE PROCESSES
4.2.2. POOR ACCESS TO THE HEALTHCARE SERVICES IN DEVELOPING MARKETS
4.2.3. MARKET IS SHIFTING FROM BRANDED TO GENERIC DRUGS
4.3. MARKET CHALLENGES
4.3.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
4.4. MARKET OPPORTUNITIES
4.4.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
5. BY TECHNOLOGY
5.1. QPCR
5.2. DNA MICROARRAYS
5.3. PROTEIN MICROARRAYS
5.4. HIGH-THROUGHPUT SCREENING
5.5. MASS SPECTROMETRY
5.6. GEL ELECTROPHORESIS
5.7. CHROMATOGRAPHY
5.8. PROTEIN AND NUCLEIC ACID ISOLATION
5.9. OTHER TECHNOLOGIES
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREATS OF NEW ENTRANTS
6.1.2. COMPETITIVE RIVALRY
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF SUBSTITUTE PRODUCTS
6.2. VALUE CHAIN ANALYSIS
6.3. KEY EXCERPTS OF THE STUDY
6.3.1. RELAXATION IN THE REGULATIONS BY THE GOVERNMENT WHICH STOPS RESEARCHERS FROM DOING RESEARCH.
6.3.2. MARKET LEADERS SHOULD OPEN UP THEIR BRANCHES AND RESEARCH LABS IN EMERGING MARKETS.
6.4. PESTLE ANALYSIS
6.5. OPPORTUNITY MATRIX
6.6. VENDOR LANDSCAPE
7. BY REGION
7.1. NORTH AMERICA
7.1.1. UNITED STATES (U.S.)
7.1.2. CANADA
7.2. EUROPE
7.2.1. UNITED KINGDOM (UK)
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE (ROE)
7.3. ASIA PACIFIC
7.3.1. INDIA
7.3.2. CHINA
7.3.3. JAPAN
7.3.4. KOREA
7.3.5. AUSTRALIA
7.3.6. REST OF ASIA-PACIFIC (ROAPAC)
7.4. REST OF THE WORLD (ROW)
7.4.1. MIDDLE EAST AND NORTH AMERICA
7.4.2. AFRICA
8. COMPANY PROFILES
8.1. SANOFI
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SWOT ANALYSIS
8.1.4. STRATEGIC ANALYSIS
8.2. JOHNSON AND JOHNSON
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SWOT ANALYSIS
8.2.4. STRATEGIC ANALYSIS
8.3. ASTRAZENECA PLC
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SWOT ANALYSIS
8.3.4. STRATEGIC ANALYSIS
8.4. BAYER AG
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SWOT ANALYSIS
8.4.4. STRATEGIC ANALYSIS
8.5. BOEHRINGER INGELHEIM
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SWOT ANALYSIS
8.5.4. STRUCTURAL ANALYSIS
8.6. PFIZER, INC.
8.6.1. COMPANY OVERVIEW
8.6.2. SWOT ANALYSIS
8.6.3. STRATEGIC ANALYSIS
8.7. GLAXOSMITHKLINE LLC
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SWOT ANALYSIS
8.7.4. STRATEGIC ANALYSIS
8.8. ELI LILY
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SWOT ANALYSIS
8.8.4. STRATEGIC ANALYSIS
8.9. MERCK & CO. INC.
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SWOT ANALYSIS
8.9.4. STRATEGIC ANALYSIS
8.10. ROCHE HOLDING AG
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SWOT ANALYSIS
8.10.4. STRATEGIC ANALYSIS
TABLE LIST
TABLE 1 FACT SHEET OF GLOBAL FATALITIES
TABLE 2 GLOBAL QPCR MARKET, BY REGION, 2016-2024, (IN $MILLION)
TABLE 3 GLOBAL DNA MICROARRAYS, BY REGION, 2016-2024, (IN $MILLION)
TABLE 4 GLOBAL PROTEIN MICROARRAYS, BY REGION, 2016-2024(IN $MILLION)
TABLE 5 GLOBAL HIGH THROUGHPUT SCREENING, BY REGION, 2016-2024(IN $MILLION)
TABLE 6 GLOBAL MASS SPECTROMETRY, BY REGION, 2016-2024(IN $MILLION)
TABLE 7 GLOBAL GEL ELECTROPHORESIS MARKET, BY REGION, 2016-2024, (IN $MILLION)
TABLE 8 GLOBAL CHROMATOGRAPHY MARKET, BY REGION, 2016-2024 (IN $MILLION)
TABLE 9 GLOBAL PROTEIN AND NUCLEIC ACID ISOLATION MARKET, BY REGION, 2016-2024 (IN $MILLION)
TABLE 10 GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, 2016-2024 (IN $MILLION)
TABLE 11 GLOBAL DRUG DISCOVERY MARKET, BY REGION, 2016-2024, (IN $MILLION)
TABLE 12 FATALITY IN EUROPE IN 2012
FIGURES LIST
FIGURE 1 GLOBAL DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 2 GLOBAL DRUG DISCOVERY MARKET SHARE, BY TECHNOLOGY, 2016 & 2024
FIGURE 3 GLOBAL QPCR MARKET, 2016-2024 (IN $MILLION)
FIGURE 4 GLOBAL DNA MICROARRAYS MARKET, 2016-2024 (IN $MILLION)
FIGURE 5 GLOBAL PROTEIN MICROARRAYS MARKET, 2016-2024 (IN $MILLION)
FIGURE 6 GLOBAL HIGH THROUGHPUT SCREENING MARKET, 2016-2024 (IN $MILLION)
FIGURE 7 GLOBAL MASS SPECTROMETRY MARKET, 2016-2024 (IN $MILLION)
FIGURE 8 GLOBAL GEL ELECTROPHORESIS MARKET, 2016-2024 (IN $MILLION)
FIGURE 9 GLOBAL CHROMATOGRAPHY MARKET, 2016-2024 (IN $MILLION)
FIGURE 10 GLOBAL PROTEIN AND NUCLEIC ACID ISOLATION MARKET, 2016-2024 (IN $MILLION)
FIGURE 11 GLOBAL OTHER TECHNOLOGIES MARKET, 2016-2024 (IN $MILLION)
FIGURE 12 NORTH AMERICA DRUG DISCOVERY MARKET, 2016-2024, (IN $ MILLION)
FIGURE 13 COUNTRY-WISE MARKET SHARE, 2016
FIGURE 14 UNITED STATES DRUG DISCOVERY MARKET, 2016-2024, (IN $ MILLION)
FIGURE 15 CANADA DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 16 EUROPE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 17 COUNTRY-WISE MARKET SHARE, 2016
FIGURE 18 UNITED KINGDOM DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 19 FRANCE DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 20 GERMAN DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 21 SPAIN DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 22 ITALY DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 23 REST OF EUROPE (ROE) DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 24 ASIA-PACIFIC DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 25 COUNTRY-WISE MARKET SHARE, 2016
FIGURE 26 INDIA DRUG DISCOVERY MARKET, 2016-2024, (IN $MILLION)
FIGURE 27 CHINA DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 28 JAPAN DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 29 KOREA DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 30 AUSTRALIA DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 31 REST OF ASIA-PACIFIC (ROAPAC) DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
FIGURE 32 REST OF THE WORLD (ROW) DRUG DISCOVERY MARKET, 2016-2024 (IN $MILLION)
